Logo

ASLAN Pharmaceutical Reports Results for Eblasakimab in Atopic Dermatitis and Chronic Obstructive Pulmonary Disease (COPD)

Share this

ASLAN Pharmaceutical Reports Results for Eblasakimab in Atopic Dermatitis and Chronic Obstructive Pulmonary Disease (COPD)

Shots:

  • The company presented data from two studies, one evaluating the differentiated MoA of eblasakimab vs dupilumab in skin punch biopsies of AD patients along with the role of eblasakimab in COPD using ex vivo models of human lungs evaluating the airway hyperresponsiveness (AHR) in the lung tissue using IL-4 & IL-13
  • The results from the study depicted that eblasakimab significantly reduced Th2 cytokines IL-13, IL-4, sCD40L, IL-17F, CCL3 & CCL4 expressions vs dupilumab whereas in COPD models, eblasakimab reduced airway constrictions & enhanced dilation
  • Results from both studies were presented at the DDDS 2023 & further data from both ongoing studies are expected to be presented at forthcoming scientific meetings

Ref: ASLAN | Image: ASLAN
Related News:- ASLAN Pharmaceuticals Entered into a License Agreement with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

 

 

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions